Direkt zum Inhalt
Merck
  • Elevated maternal cortisol leads to relative maternal hyperglycemia and increased stillbirth in ovine pregnancy.

Elevated maternal cortisol leads to relative maternal hyperglycemia and increased stillbirth in ovine pregnancy.

American journal of physiology. Regulatory, integrative and comparative physiology (2014-06-13)
Maureen Keller-Wood, Xiaodi Feng, Charles E Wood, Elaine Richards, Russell V Anthony, Geoffrey E Dahl, Sha Tao
ZUSAMMENFASSUNG

In normal pregnancy, cortisol increases; however, further pathological increases in cortisol are associated with maternal and fetal morbidities. These experiments were designed to test the hypothesis that increased maternal cortisol would increase maternal glucose concentrations, suppress fetal growth, and impair neonatal glucose homeostasis. Ewes were infused with cortisol (1 mg·kg(-1)·day(-1)) from day 115 of gestation to term; maternal glucose, insulin, ovine placental lactogen, estrone, progesterone, nonesterified free fatty acids (NEFA), β-hydroxybutyrate (BHB), and electrolytes were measured. Infusion of cortisol increased maternal glucose concentration and slowed the glucose disappearance after injection of glucose; maternal infusion of cortisol also increased the incidence of fetal death at or near parturition. The design of the study was altered to terminate the study prior to delivery, and post hoc analysis of the data was performed to test the hypothesis that maternal metabolic factors predict the fetal outcome. In cortisol-infused ewes that had stillborn lambs, plasma insulin was increased relative to control ewes or cortisol-infused ewes with live lambs. Maternal cortisol infusion did not alter maternal food intake or plasma NEFA, BHB, estrone, progesterone or placental lactogen concentrations, and it did not alter fetal body weight, ponderal index, or fetal organ weights. Our study suggests that the adverse effect of elevated maternal cortisol on pregnancy outcome may be related to the effects of cortisol on maternal glucose homeostasis, and that chronic maternal stress or adrenal hypersecretion of cortisol may create fetal pathophysiology paralleling some aspects of maternal gestational diabetes.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Hydrocortison, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydrocortison, γ-irradiated, powder, BioXtra, suitable for cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Ethylendiamintetraessigsäure -Lösung, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydrocortison, ≥98% (HPLC)
Sigma-Aldrich
Ethylendiamintetraessigsäure, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, 99.995% trace metals basis
Sigma-Aldrich
Ethylendiamintetraessigsäure, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
Ethylendiamintetraessigsäure Dinatriumsalz -Lösung, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
Ethylendiamintetraessigsäure, purified grade, ≥98.5%, powder
Supelco
Hydrocortison, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Hydrocortison, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethylendiamintetraessigsäure, ≥98.0% (KT)
Sigma-Aldrich
Hydrocortison, meets USP testing specifications
Sigma-Aldrich
Ethylendiamintetraessigsäure, BioUltra, ≥99.0% (KT)
Hydrocortison für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Hydrocortison, European Pharmacopoeia (EP) Reference Standard
Supelco
Hydrocortison-21-Hemisuccinat, analytical standard
Hydrocortison, British Pharmacopoeia (BP) Assay Standard
Hydrocortisonhydrogensuccinat, European Pharmacopoeia (EP) Reference Standard